Spots Global Cancer Trial Database for mixed oligoastrocytoma
Every month we try and update this database with for mixed oligoastrocytoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | NCT00041587 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Safety Study of Afatinib for Brain Cancer | NCT02423525 | Brain Cancer | Afatinib | 18 Years - | Saint John's Cancer Institute | |
| Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | NCT00024570 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | NCT00024557 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... Malignant Astro... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Safety Study of Afatinib for Brain Cancer | NCT02423525 | Brain Cancer | Afatinib | 18 Years - | Saint John's Cancer Institute | |
| Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | NCT00064779 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | NCT02372409 | Glioma Pilocytic Astro... Anaplastic Astr... Glioblastoma Mixed Oligoastr... Mixed Glioma Oligodendroglio... Optic Glioma Astrocytoma | MRI-guided lase... Doxorubicin Etoposide Dynamic contras... Dynamic suscept... | 3 Years - 21 Years | Washington University School of Medicine | |
| Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | NCT00024570 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | NCT00064779 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Prolonged Daily Temozolomide for Low-Grade Glioma | NCT00165360 | Glioma Astrocytoma Oligodendroglio... | Temozolomide | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
